Psychotherapeutic drugs are medications that treat mental health conditions by altering brain chemistry. They work primarily by changing how neurotransmitters (the brain’s chemical messengers) are produced, absorbed, or used. The five major classes are antidepressants, antipsychotics, anxiolytics, mood stabilizers, and stimulants, each targeting different symptoms and disorders.
These drugs don’t fit into neat boxes the way you might expect. An antidepressant might also treat anxiety, chronic pain, or PTSD. An antipsychotic approved for schizophrenia might be prescribed for bipolar depression or as a boost to an antidepressant that isn’t working well enough on its own. Understanding the major categories is still useful, but the boundaries between them are blurry in practice.
Antidepressants
Antidepressants are the most widely prescribed class of psychotherapeutic drugs. They increase the availability of certain neurotransmitters, particularly serotonin and norepinephrine, which play key roles in regulating mood, sleep, and motivation. There are several subtypes, and they differ mainly in which brain chemicals they target and what side effects they carry.
SSRIs (selective serotonin reuptake inhibitors) are the most commonly used. They work by blocking the brain’s reabsorption of serotonin, leaving more of it available between nerve cells. They became popular because they cause fewer side effects than older options.
SNRIs (serotonin-norepinephrine reuptake inhibitors) block the reabsorption of both serotonin and norepinephrine. Because they act on two chemical systems instead of one, they are sometimes called “dual-action” antidepressants. Medications like venlafaxine and duloxetine fall into this category and are often prescribed when an SSRI alone hasn’t been effective enough, or when pain is part of the picture.
Older classes include tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). MAOIs work differently: instead of blocking reabsorption, they prevent the enzyme that breaks down serotonin and norepinephrine, so more of both chemicals stay active. TCAs and MAOIs are effective but carry more significant side effects and dietary or drug interaction risks, so they’re typically reserved for cases where newer medications haven’t worked.
SSRIs have proven effective well beyond depression. They are used for generalized anxiety disorder, panic disorder, social anxiety, PTSD, obsessive-compulsive disorder, and premenstrual dysphoric disorder. Most guidelines recommend continuing antidepressants for at least four to six months after symptoms improve to prevent relapse, and longer for people who have experienced multiple depressive episodes.
Antipsychotics
Antipsychotics primarily treat conditions involving psychosis, such as schizophrenia, but they are also used for bipolar disorder, severe agitation, and as add-on therapy for depression that doesn’t respond to antidepressants alone. They come in two generations with meaningfully different profiles.
First-generation (typical) antipsychotics work mainly by blocking dopamine receptors in the brain. Dopamine overactivity in certain brain pathways is linked to hallucinations, delusions, and disorganized thinking. These older drugs are effective, but their strong grip on dopamine receptors also affects brain regions that control movement, which can cause stiffness, tremors, and involuntary muscle movements over time.
Second-generation (atypical) antipsychotics bind less tightly to dopamine receptors and also act on serotonin receptors. This combination generally produces fewer movement-related side effects, though atypical antipsychotics are more likely to cause weight gain and metabolic changes like increased blood sugar or cholesterol. Some atypical antipsychotics, such as quetiapine and lurasidone, are specifically effective as stand-alone treatments for bipolar depression.
A notable recent addition is Cobenfy, approved by the FDA in September 2024. It treats schizophrenia through an entirely different mechanism: instead of blocking dopamine, it works through the brain’s cholinergic system. This represents the first truly new approach to schizophrenia treatment in decades.
Both generations of antipsychotics carry an FDA boxed warning about increased risk of death when used in elderly patients with dementia-related psychosis. This warning applies to every antipsychotic on the market.
Anxiolytics
Anxiolytics reduce anxiety, and the best-known group is benzodiazepines. These drugs work on GABA receptors, the brain’s primary system for slowing neural activity. Normally, GABA acts like a brake on the nervous system. Benzodiazepines enhance that braking effect by shifting GABA receptors into a more responsive state, so the brain’s natural calming signals become stronger. The result is reduced anxiety, muscle relaxation, and sedation.
Benzodiazepines work quickly, often within 30 minutes, which makes them useful for acute anxiety or panic attacks. The tradeoff is that the brain adapts to them relatively fast. Tolerance can develop within weeks, meaning the same dose produces less effect over time. Physical dependence is a real concern with regular use, and stopping abruptly after prolonged use can cause withdrawal symptoms including rebound anxiety, insomnia, and in severe cases, seizures. For these reasons, benzodiazepines are generally intended for short-term use.
Other medications with anti-anxiety effects, such as SSRIs and SNRIs, are often preferred for long-term anxiety management because they don’t carry the same dependence risk. Buspirone is another non-benzodiazepine option that works on serotonin receptors and takes several weeks to reach full effectiveness.
Mood Stabilizers
Mood stabilizers are the cornerstone of bipolar disorder treatment, designed to prevent the extreme highs of mania and the lows of depression without simply flattening emotions. Lithium is the oldest and most studied mood stabilizer, and it remains one of the most effective. Certain anti-seizure medications, particularly valproate, also function as mood stabilizers and are used for bipolar disorder, aggression, and other conditions.
Lithium requires regular blood monitoring because the effective dose and the toxic dose are not far apart. The typical target blood level for maintenance treatment is 0.6 to 0.8 mmol/L. Going above this range increases the risk of toxicity, which can affect the kidneys, thyroid, and other organs.
Long-term lithium use has specific health considerations. Kidney function declines about 30% more than it would from aging alone, and this decline can become irreversible. Up to 40% of people on lithium develop an enlarged thyroid gland, and roughly 20% develop an underactive thyroid. Lithium also tends to raise calcium and parathyroid hormone levels by about 10%, which can lead to further complications over time. Because of these risks, people taking lithium need regular blood work to monitor kidney function, thyroid levels, and lithium concentration.
Stimulants
Stimulants are the primary treatment for attention deficit hyperactivity disorder (ADHD). They might seem counterintuitive for a condition associated with hyperactivity, but they work by boosting activity in the prefrontal cortex, the brain region responsible for focus, planning, and impulse control.
The two main types are methylphenidate-based and amphetamine-based medications. Both block the reabsorption of dopamine and norepinephrine, increasing the availability of these chemicals at nerve connections. In the prefrontal cortex specifically, there are relatively few dopamine transporters, so the effect in this region may depend more on blocking norepinephrine transporters. The net result is improved concentration, reduced impulsivity, and better executive function.
Stimulants take effect quickly, often within an hour, and come in short-acting and extended-release formulations. Common side effects include reduced appetite, difficulty sleeping, and increased heart rate. Because stimulants have potential for misuse, they are classified as controlled substances.
Stopping Psychotherapeutic Drugs Safely
One important reality that applies across nearly all psychotherapeutic drug classes is that stopping suddenly can cause problems. Discontinuation syndrome, a set of physical and psychological symptoms that emerge when a medication is stopped too quickly, is well-documented with antidepressants, benzodiazepines, and other psychotropic medications. Symptoms can include dizziness, nausea, irritability, sleep disruption, and sensory disturbances that are sometimes mistaken for a return of the original condition.
Despite how common this issue is, there is surprisingly little formal guidance on the best way to taper each class of medication. The general principle is gradual dose reduction over weeks or months rather than abrupt cessation, with the pace depending on how long you’ve been taking the medication, the dose, and the specific drug involved. People on low doses for short periods can sometimes stop without a taper, while those on higher doses or longer durations typically need a slower, more careful reduction.